Belkin Vision Announces FDA Clearance for the Eagle for Selective Laser Trabeculoplasty
Belkin Vision has received FDA 510(k) clearance for the Eagle device, a Q-switched, 532 nm-wavelength, frequency-doubled Nd:YAG laser intended for use in performing selective laser trabeculoplasty (SLT).
Belkin describes the Eagle as the first and only contactless laser for glaucoma, providing an automated and noninvasive solution for patients and healthcare professionals. The Eagle offers several advantages over traditional treatment options, according to Belkin. First, the laser energy is delivered in a non-contact procedure directly through the limbus to the trabecular meshwork without the need for the use of a gonioscopy lens. In addition, the device automatically defines the target location then applies the laser treatment sequence while the eye tracker compensates for any eye movement. By introducing Direct-SLT (DSLT), a streamlined, user-friendly technology, Belkin aims to expand access to early laser therapy for more patients by enabling a larger number of eye care professionals to perform the procedure.
"This achievement has been possible thanks to the skill, passion, and dedication of our entire team. We believe that this FDA clearance will have a positive impact on the lives of those affected by glaucoma, offering novel treatment methods and renewed hope for the future," Belkin Vision CEO, Daria Lemann-Blumenthal, said in a company news release.